615
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma

ORCID Icon, , , , , ORCID Icon, , , , ORCID Icon & ORCID Icon show all
Pages 2233-2237 | Received 22 Dec 2021, Accepted 09 Apr 2022, Published online: 09 May 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (2)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.